Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPA | P38571 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 3/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20286470 | 0.91 | PDE4A (0.33) | LIPACNR1CNR2NAMPTPDE4D | |
| SCHEMBL13727465 | 0.88 | LIPA (0.42) | LIPACNR1CNR2RIPK1 | |
| SCHEMBL17445699 | 0.85 | LIPA (0.35) | LIPA | |
| SCHEMBL19881202 | 0.81 | CNR1 (0.30) | LIPACNR1CNR2 | |
| SCHEMBL13616894 | 0.79 | — | — | |
| SCHEMBL16790679 | 0.79 | — | — | |
| SCHEMBL8406312 | 0.78 | LIPA (0.52) | LIPANAMPT | |
| SCHEMBL628315 | 0.77 | — | — | |
| SCHEMBL1691652 | 0.77 | — | — | |
| SCHEMBL628314 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802105-B2 | Treprostinil derivatives and compositions and uses thereof | Corsair Pharma, Inc. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BEONE MEDICINES I GMBH (CH) | 2023-07-13 | — | — | US | disclosed |
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-02-02 | — | — | US | disclosed |
| US-20220378743-A1 | METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2022-12-01 | — | — | US | disclosed |
| US-11130749-B2 | — | — | 2021-09-28 | — | — | US | disclosed |
| US-10988435-B2 | Treprostinil derivatives and compositions and uses thereof | Corsair Pharma, Inc. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200347006-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | Corsair Pharma, Inc. (US) | 2020-11-05 | — | — | US | disclosed |
| US-10703706-B2 | Treprostinil derivatives and compositions and uses thereof | Corsair Pharma, Inc. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2019-09-12 | — | — | US | disclosed |
| US-20190241499-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | CORSAIR PHARMA INC (US) | 2019-08-08 | — | — | US | disclosed |
| US-10202345-B2 | Substituted azaspiro(4.5)decane derivatives | GRUENENTHAL GMBH (DE) | 2019-02-12 | — | — | US | disclosed |
| US-20180170855-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | Corsair Pharma, Inc. | 2018-06-21 | — | — | US | disclosed |
| US-20180170855-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | Corsair Pharma, Inc. | 2018-06-21 | — | — | US | disclosed |
| US-20160016903-A1 | Substituted Azaspiro(4.5)Decane Derivatives | GRUENENTHAL GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202345-B2 | Substituted azaspiro(4.5)decane derivatives | OPRL1, OPRD1, OPRM1 | LIPA 2393/4885CNR1 37/4885CNR2 70/4885 |
| US-20200347006-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | PTGIS, PTGIR, PDE3A | LIPA 1403/4885CNR1 2407/4885CNR2 1902/4885 |
| US-20190241499-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | PTGIS, PTGIR, PDE3A | LIPA 1403/4885CNR1 2407/4885CNR2 1902/4885 |
| US-10988435-B2 | Treprostinil derivatives and compositions and uses thereof | PTGIS, PTGIR, PDE3A | LIPA 1403/4885CNR1 2407/4885CNR2 1902/4885 |
| US-10703706-B2 | Treprostinil derivatives and compositions and uses thereof | PTGIS, PTGIR, PDE3A | LIPA 1403/4885CNR1 2407/4885CNR2 1902/4885 |
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BIRC2, BIRC3, API5 | LIPA 4831/4885CNR1 1957/4885CNR2 2424/4885 |
| US-11802105-B2 | Treprostinil derivatives and compositions and uses thereof | PTGIS, PTGIR, PDE3A | LIPA 1403/4885CNR1 2407/4885CNR2 1902/4885 |
| US-20180170855-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | PTGIS, PTGIR, PDE3A | LIPA 1403/4885CNR1 2407/4885CNR2 1902/4885 |
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | LIPA 1362/4885CNR1 4082/4885CNR2 3964/4885 |
| US-11130749-B2 | — | ROCK1, RHOA, ROCK2 | LIPA 929/4885CNR1 3908/4885CNR2 3993/4885 |
| US-20160016903-A1 | Substituted Azaspiro(4.5)Decane Derivatives | OPRL1, OPRD1, OPRM1 | LIPA 2393/4885CNR1 37/4885CNR2 70/4885 |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | LIPA 1362/4885CNR1 4082/4885CNR2 3964/4885 |
| US-20220378743-A1 | METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS | SLC10A1, CYP7A1, FABP1 | LIPA 65/4885CNR1 1048/4885CNR2 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.